Toxicology – Antineoplastic Medications

Core Concept

Antineoplastic drugs comprise many pharmacologically unrelated agents used to treat malignancy. Some, particularly methotrexate, are also used for nonmalignant diseases.

Unlike many medication ingestions, antineoplastic overdose is potentially serious because toxicity may be:

• Delayed
• Multisystem
• Prolonged
• Dose- and route-dependent
• Associated with profound myelosuppression
• Complicated by renal, hepatic, cardiac, neurologic, or pulmonary injury

A patient can initially appear well and subsequently develop severe toxicity days or even weeks later.

Management therefore requires identification of the exact drug, route, dose, timing, and treatment protocol, usually with early toxicology and oncology involvement.

Major Antineoplastic Classes

Important groups include:

Antimetabolites

• Methotrexate
• 5-fluorouracil (5-FU)
• Cytarabine

Alkylating agents

• Cyclophosphamide
• Ifosfamide
• Melphalan
• Chlorambucil
• Mechlorethamine
• Carmustine
• Lomustine

Platinum compounds

• Cisplatin
• Carboplatin
• Oxaliplatin

Anthracyclines

• Doxorubicin
• Daunorubicin

Vinca alkaloids

• Vincristine
• Vinblastine

Topoisomerase inhibitors

• Etoposide

Microtubule-stabilizing agents

• Paclitaxel and related taxanes

Other cytotoxic agents

• Bleomycin
• Dactinomycin
• Mitomycin
• Asparaginase

Modern oncology also includes targeted therapies, monoclonal antibodies, immune checkpoint inhibitors, antibody-drug conjugates, and other agents whose toxicity differs substantially from traditional cytotoxic chemotherapy.

Why Antineoplastic Toxicity Is Different

Many cytotoxic drugs preferentially injure rapidly dividing cells.

Consequently, major target tissues include:

• Bone marrow
• GI epithelium
• Oral mucosa
• Hair follicles
• Reproductive tissues

Individual drugs additionally have characteristic organ toxicities.

A useful framework is:

Exposure → early GI/mucosal toxicity → delayed marrow suppression ± agent-specific organ injury

Delayed Toxicity

A critical toxicology principle is that absence of early symptoms does not exclude severe poisoning.

Delayed complications may include:

• Neutropenia
• Thrombocytopenia
• Anemia
• Mucositis
• Infection
• Sepsis
• Bleeding
• Organ failure

Some agents, particularly nitrosoureas, can cause marrow suppression substantially later than the classic first 1–2 weeks.

1. Methotrexate

Methotrexate inhibits dihydrofolate reductase, impairing tetrahydrofolate production and nucleotide synthesis.

Major toxicities include:

• Mucositis
• Myelosuppression
• GI injury
• Hepatotoxicity
• Nephrotoxicity
• Neurotoxicity
• Pulmonary toxicity

High-dose therapy is particularly dangerous when renal elimination becomes impaired.

Methotrexate Nephrotoxicity

Methotrexate and its metabolites may precipitate within renal tubules.

This can produce:

Crystal nephropathy → reduced clearance → rising methotrexate concentration → further toxicity

This creates a potentially dangerous positive-feedback cycle.

Risk increases with:

• High-dose therapy
• Dehydration
• Acidic urine
• Preexisting renal impairment
• Interacting medications

Methotrexate Drug Interactions

Medications that interfere with renal clearance can increase toxicity.

Examples may include:

• NSAIDs
• Certain antibiotics
• Proton-pump inhibitors in some high-dose settings
• Other nephrotoxic or renally competing medications

Medication review is therefore essential when methotrexate elimination is delayed.

Methotrexate – Leucovorin Rescue

Leucovorin (folinic acid) bypasses the folate pathway blocked by methotrexate and is a central rescue therapy for clinically important systemic methotrexate toxicity.

The amount and duration of leucovorin depend on:

• Methotrexate concentration
• Time since administration
• Renal function
• Evidence of delayed elimination
• Clinical toxicity

Historical fixed concentration cutoffs should not substitute for the appropriate treatment protocol or nomogram.

Glucarpidase

A major modern addition is glucarpidase.

It rapidly metabolizes circulating methotrexate through a pathway independent of renal clearance.

It may be indicated in selected patients with:

High-dose methotrexate + delayed elimination + significant renal dysfunction

Leucovorin therapy remains important, but its timing relative to glucarpidase matters and should follow specialist protocols.

Methotrexate Hydration and Urinary Alkalinization

High-dose methotrexate toxicity is managed with carefully controlled:

• IV hydration
• Urinary alkalinization
• Serial methotrexate concentrations
• Serial renal function
• Leucovorin rescue

The aim is to improve methotrexate solubility and renal elimination.

Exact fluid and bicarbonate regimens are protocol-specific rather than universal overdose formulas.

Methotrexate Routes Matter

Toxicity differs markedly between:

• Single acute oral exposure
• Repeated low-dose dosing errors
• High-dose IV chemotherapy
• Intrathecal exposure

A particularly important modern problem is accidental daily instead of weekly methotrexate dosing in patients prescribed low-dose therapy.

Repeated dosing errors can cause severe:

• Mucositis
• Pancytopenia
• Infection
• Bleeding
• Renal/hepatic injury

Intrathecal Methotrexate

Excessive intrathecal exposure can cause severe neurotoxicity, including:

• Headache
• Meningeal irritation
• Encephalopathy
• Seizures
• Motor deficits
• Leukoencephalopathy

This is a specialized emergency requiring immediate consultation with oncology, toxicology, neurology/neurosurgery, and other appropriate specialists.

Historical invasive CSF-exchange procedures should not be treated as routine bedside instructions.

2. 5-Fluorouracil – 5-FU

5-FU interferes with pyrimidine metabolism, particularly through inhibition of thymidylate synthase, while metabolites can also become incorporated into RNA and DNA.

Major toxicities include:

• Severe mucositis
• Diarrhea
• Myelosuppression
• Neurotoxicity
• Cardiotoxicity

5-FU Cardiotoxicity

5-FU can produce:

• Coronary vasospasm
• Chest pain
• Myocardial ischemia
• Dysrhythmia
• Cardiomyopathy
• Rare cardiogenic shock

Cardiac symptoms during infusion require prompt evaluation and cessation of the offending therapy.

5-FU and DPD Deficiency

A major modern concept is dihydropyrimidine dehydrogenase (DPD) deficiency.

DPD is crucial for fluoropyrimidine metabolism.

Reduced DPD activity can result in unexpectedly severe toxicity even with standard treatment.

Possible manifestations include:

• Profound diarrhea
• Mucositis
• Neutropenia
• Encephalopathy
• Multiorgan toxicity

Uridine Triacetate

Another major modernization is uridine triacetate, a specific emergency antidotal therapy for severe fluoropyrimidine toxicity.

It is used for selected:

• 5-FU overdoses
• Capecitabine overdoses
• Early severe/life-threatening fluoropyrimidine toxicity

Benefit is highly time dependent, so suspected serious fluoropyrimidine overdose warrants immediate specialist/poison-center consultation.

The historical suggestion that allopurinol prevents 5-FU overdose-related marrow suppression is not modern standard antidotal management.

3. Cytarabine

Cytarabine is a cytidine analog that inhibits DNA synthesis.

High systemic exposure can cause:

• Myelosuppression
• Mucositis
• Hepatic dysfunction
• Neurotoxicity

A characteristic complication of high-dose therapy is cerebellar toxicity.

Cytarabine Neurotoxicity

Possible findings include:

• Dysarthria
• Nystagmus
• Ataxia
• Dysmetria
• Confusion
• Encephalopathy

Risk increases with:

• Older age
• Renal dysfunction
• High-dose therapy

Serial neurologic examination is therefore important during high-dose treatment.

4. Cisplatin and Carboplatin

Platinum agents produce DNA cross-linking.

Cisplatin

Particularly associated with:

• Nephrotoxicity
• Ototoxicity
• Peripheral neuropathy
• Severe nausea/vomiting
• Electrolyte wasting

Carboplatin

More prominently associated with:

• Myelosuppression, especially thrombocytopenia

while generally being less nephrotoxic than cisplatin.

Cisplatin Electrolyte Toxicity

Renal tubular injury can produce:

• Hypomagnesemia
• Hypokalemia
• Hypocalcemia
• Other electrolyte abnormalities

Monitor:

• Creatinine
• Magnesium
• Potassium
• Calcium

Ototoxicity may manifest as tinnitus or high-frequency sensorineural hearing loss.

5. Cyclophosphamide and Ifosfamide

These alkylating agents generate toxic metabolites capable of injuring the urinary tract.

A classic complication is:

Hemorrhagic cystitis

Manifestations include:

• Dysuria
• Hematuria
• Bladder irritation

Mesna

Mesna binds urotoxic metabolites within the urinary tract and is used to prevent hemorrhagic cystitis associated particularly with ifosfamide and high-risk cyclophosphamide regimens.

Adequate hydration is also important.

This is more specific and clinically useful than relying on extremely high fixed fluid volumes from older toxicology references.

Ifosfamide Encephalopathy

Ifosfamide can cause:

• Confusion
• Somnolence
• Hallucinations
• Agitation
• Seizures
• Coma

Renal tubular dysfunction and metabolic abnormalities can also occur.

Selected severe cases of ifosfamide encephalopathy may be treated with methylene blue, although evidence is limited and specialist guidance is appropriate.

Cyclophosphamide Cardiotoxicity

High systemic exposure can cause:

• Myocardial injury
• Arrhythmia
• Heart failure
• Hemorrhagic myocarditis in severe cases

This is primarily associated with intensive treatment regimens rather than ordinary low-dose exposure.

6. Anthracyclines – Doxorubicin and Daunorubicin

Anthracyclines interfere with topoisomerase II, DNA function, and oxidative cellular pathways.

Important toxicities include:

• Myelosuppression
• Mucositis
• Cardiotoxicity
• Severe tissue injury after extravasation

Anthracycline Cardiotoxicity

Cardiac toxicity may be:

Acute

• ECG abnormalities
• Dysrhythmia
• Myopericarditis
• Transient ventricular dysfunction

Chronic

• Progressive cardiomyopathy
• Reduced ejection fraction
• Heart failure

Chronic risk generally rises with cumulative exposure but cannot be represented by a single universal dose cutoff because risk depends on the specific anthracycline and patient factors.

Dexrazoxane

Dexrazoxane can reduce anthracycline-related cardiac injury in selected treatment settings.

It also has an important modern role as an antidotal treatment for anthracycline extravasation.

Its use is indication- and timing-specific and should follow oncology/extravasation protocols.

7. Vinca Alkaloids

Vincristine

Toxicity is predominantly neurologic.

Possible manifestations include:

• Peripheral neuropathy
• Paresthesias
• Weakness
• Reduced reflexes
• Autonomic dysfunction
• Ileus
• Cranial neuropathies
• SIADH
• Severe neurotoxicity after excessive exposure

Vinblastine

Produces relatively more:

• Myelosuppression

although neurologic toxicity can also occur.

Vincristine – Intrathecal Exposure

Intrathecal vincristine is a catastrophic medical error and can be fatal.

Vincristine must never be administered intrathecally.

This requires immediate specialist emergency management.

Older descriptions of specific CSF-perfusion procedures should not be treated as a standard or universally effective antidote.

Prevention through safe chemotherapy systems is critical.

Vincristine Interactions

Vincristine neurotoxicity can be substantially increased by medications that impair its metabolism.

Clinically important interactions include some strong CYP3A inhibitors, particularly certain azole antifungals.

Medication reconciliation is therefore essential.

8. Etoposide

Etoposide inhibits topoisomerase II.

Major adverse effects include:

• Myelosuppression
• Nausea/vomiting
• Mucositis
• Hepatic injury at high exposure
• Hypersensitivity

Rapid IV administration can produce hypotension.

9. Paclitaxel

Paclitaxel stabilizes microtubules and prevents normal mitotic function.

Important adverse effects include:

• Neutropenia
• Peripheral neuropathy
• Hypersensitivity reactions
• Myalgias/arthralgias
• Cardiac conduction abnormalities in selected patients
• Mucositis

Acute overdose can produce severe marrow and neurologic toxicity.

10. Bleomycin

Bleomycin causes DNA strand injury.

Its characteristic dose-limiting organ toxicity is:

Pulmonary injury

Possible manifestations include:

• Dry cough
• Dyspnea
• Interstitial pneumonitis
• Pulmonary fibrosis

Bleomycin and Oxygen – Important Nuance

Older teaching sometimes implied that oxygen should simply be avoided in anyone previously exposed to bleomycin.

That is too absolute.

Hypoxemia must be treated.

However, unnecessary prolonged exposure to excessive inspired oxygen should be avoided when lower concentrations adequately maintain oxygenation, particularly in patients with established bleomycin lung injury.

11. Asparaginase

Asparaginase reduces circulating asparagine and interferes with protein synthesis in susceptible malignant cells.

Major toxicities include:

• Hypersensitivity/anaphylaxis
• Pancreatitis
• Hepatic dysfunction
• Hyperglycemia
• Thrombosis
• Bleeding/coagulopathy

Coagulation abnormalities reflect disruption of hepatic synthesis of both procoagulant and anticoagulant proteins.

12. Nitrosoureas

Carmustine and lomustine can produce particularly delayed myelosuppression.

Important effects include:

• Thrombocytopenia
• Leukopenia
• Pulmonary toxicity
• Hepatic injury
• Renal injury
• CNS effects at high exposure

Marrow nadir may occur several weeks after treatment.

Therefore, short ED observation cannot exclude serious toxicity.

13. Procarbazine

Procarbazine has weak monoamine oxidase-inhibiting properties.

Potential adverse effects include:

• Myelosuppression
• GI symptoms
• Neuropathy
• CNS disturbances

Clinically important medication and dietary interactions should be considered during therapy, although the interaction profile should not simply be extrapolated from classic irreversible MAO inhibitors.

14. Extravasation

Several antineoplastic drugs can cause substantial local tissue injury if they escape from the vein.

Possible manifestations include:

• Burning
• Pain
• Swelling
• Erythema
• Blistering
• Ulceration
• Tissue necrosis

Vesicants

Important vesicant drugs include:

• Anthracyclines
• Vinca alkaloids
• Mechlorethamine
• Mitomycin
• Several other cytotoxic agents

Management is drug specific.

Extravasation Management

General priorities include:

• Stop the infusion immediately
• Leave vascular access available initially when appropriate for aspiration/antidotal management
• Avoid flushing the infiltrated line
• Identify the exact drug
• Elevate the affected limb when appropriate
• Follow the agent-specific cold/warm compress protocol
• Obtain oncology/pharmacy/extravasation specialist guidance

The older recommendation to inject saline into the site to “dilute” the drug is not a universal modern approach and may spread the vesicant further.

Extravasation Antidotes

Depending on the drug, modern antidotal strategies may include:

• Dexrazoxane for anthracycline extravasation
• Hyaluronidase for selected vinca alkaloid/taxane extravasations
• Sodium thiosulfate for selected mechlorethamine-related injuries

Antidote choice, compress temperature, and technique are drug specific.

Routine corticosteroid infiltration is not a universal treatment.

Myelosuppression

Myelosuppression is one of the most important delayed complications of cytotoxic chemotherapy.

It can cause:

• Neutropenia → infection/sepsis
• Thrombocytopenia → bleeding
• Anemia → fatigue, dyspnea, tissue hypoxia

The timing of nadir differs substantially between agents.

Neutropenic Fever

Fever in a significantly neutropenic patient after chemotherapy is an oncologic emergency.

Management includes:

• Immediate clinical assessment
• Blood cultures and appropriate infection evaluation
• Prompt empiric antimicrobial therapy according to febrile-neutropenia protocols

Treatment should not be delayed while waiting for culture results.

Growth Factors

Granulocyte colony-stimulating factors such as filgrastim may be used in selected chemotherapy-associated neutropenia or overdose situations.

Use depends on:

• Agent involved
• Severity and expected duration of neutropenia
• Infection status
• Oncology/toxicology recommendations

A single historical neutrophil threshold is insufficient to determine use.

Laboratory Evaluation

Important baseline studies after significant antineoplastic overdose may include:

• CBC with differential
• Platelet count
• Electrolytes
• Glucose
• BUN/creatinine
• Liver tests

Additional studies depend on the drug.

Agent-Specific Testing

Methotrexate

• Serial methotrexate concentrations
• Creatinine
• Urine pH when high-dose toxicity is relevant

Cisplatin/carboplatin

• Magnesium
• Potassium
• Calcium
• Renal function
• Audiometry when indicated

Cyclophosphamide/ifosfamide

• Urinalysis
• Renal function
• Electrolytes
• Acid–base status

Anthracyclines

• ECG
• Cardiac biomarkers when clinically indicated
• Echocardiography for suspected myocardial dysfunction

Bleomycin

• Oxygenation
• Pulmonary imaging/function assessment when symptomatic

Serial CBC Is Essential

A normal initial CBC does not exclude future severe marrow suppression.

Repeat testing must be scheduled according to:

• Drug
• Dose
• Expected nadir
• Clinical condition

This is one of the most important follow-up principles in antineoplastic poisoning.

GI Decontamination

Do not induce vomiting.

Ipecac is obsolete.

Routine gastric lavage is obsolete.

Activated charcoal may occasionally be considered after a clinically important recent oral exposure when:

• The agent is adsorbable
• Airway protection is adequate
• Aspiration risk is acceptable
• Expected benefit outweighs risk

Many antineoplastic overdoses occur through parenteral medication errors, where GI decontamination has no role.

Seizures

For toxicologic seizures:

Benzodiazepines are first-line.

Persistent seizures may require:

• Additional benzodiazepines
• Phenobarbital
• Appropriate anesthetic therapy for refractory status epilepticus

Correct contributing:

• Hypoglycemia
• Electrolyte abnormalities
• Hypoxia
• Acid–base disturbances

Hypotension

Identify the mechanism, such as:

• Volume depletion
• Rapid infusion reaction
• Anaphylaxis
• Cardiogenic shock
• Sepsis
• Coingestant

Use appropriate isotonic fluid when indicated.

Vasopressor selection should be based on shock physiology; norepinephrine is generally preferred for persistent vasodilatory shock.

Trendelenburg positioning and routine dopamine-first therapy are outdated.

Dysrhythmias

There is no universal antineoplastic-associated dysrhythmia treatment.

Management depends on:

• Exact drug
• Rhythm
• QRS duration
• QT interval
• Electrolytes
• Myocardial function
• Hemodynamic stability

The older routine sequence of bicarbonate → lidocaine → bretylium is not a modern universal chemotherapy-overdose algorithm.

Bretylium is obsolete in routine contemporary resuscitation.

Dialysis and Extracorporeal Treatment

Extracorporeal removal is highly agent dependent.

It cannot be generalized across antineoplastic drugs.

For example, severe delayed methotrexate elimination is now approached with:

• Leucovorin
• Hydration
• Urinary alkalinization
• Glucarpidase when indicated

rather than assuming conventional dialysis is the optimal method of drug removal.

Renal replacement therapy remains appropriate for conventional severe renal/metabolic indications.

Monitoring

Significant antineoplastic overdose may require monitoring for:

• Delayed cytopenias
• Infection
• Bleeding
• Mucositis
• Renal failure
• Hepatic injury
• Electrolyte abnormalities
• Cardiac dysfunction
• Neurotoxicity
• Pulmonary toxicity

The monitoring period can extend for days to weeks depending on the agent.

Disposition

A universal “6-hour observation then discharge” approach is inappropriate.

Disposition depends on:

• Exact drug
• Dose
• Route
• Time since exposure
• Renal/hepatic function
• Initial symptoms
• Expected delayed toxicity
• Ability to obtain serial laboratory testing
• Reliability of oncology/toxicology follow-up

A clinically well patient may still require carefully scheduled outpatient CBC and organ-function monitoring.

Admission

Hospitalization is appropriate for clinically important exposures associated with:

• Significant methotrexate accumulation
• Severe mucositis
• Neutropenia
• Febrile neutropenia
• Thrombocytopenia/bleeding
• Severe anemia
• AKI
• Major electrolyte abnormalities
• Hepatic failure
• Encephalopathy
• Seizures
• Cardiac toxicity
• Pulmonary toxicity
• Serious extravasation
• Significant fluoropyrimidine overdose

ICU care may be necessary for shock, respiratory failure, malignant dysrhythmia, status epilepticus, severe sepsis, or multiorgan failure.

Pregnancy

The historical FDA pregnancy letter categories are obsolete.

Many traditional cytotoxic antineoplastics can cause:

• Embryotoxicity
• Fetotoxicity
• Teratogenicity
• Fetal growth effects

However, cancer treatment during pregnancy is highly dependent on:

• Specific drug
• Gestational age
• Cancer type
• Disease urgency
• Treatment alternatives

Pregnancy is therefore not appropriately summarized by a single class-wide prohibition.

Safeguarding and Medication Error

Antineoplastic overdose is frequently iatrogenic, making systems analysis important.

Potential causes include:

• Wrong dose
• Wrong route
• Wrong infusion rate
• Wrong schedule
• Confusion between daily and weekly dosing
• Intrathecal/intravenous route errors
• Pump programming errors

Prevention and rapid recognition of chemotherapy medication errors are major components of toxicology care.

Rigid age cutoffs for assuming abuse or intentional poisoning are outdated.

Prognosis

Outcome varies enormously by drug and exposure.

Important causes of morbidity and mortality include:

• Neutropenic sepsis
• Severe thrombocytopenic bleeding
• Multiorgan failure
• AKI
• Cardiomyopathy
• Pulmonary fibrosis
• Severe neurotoxicity
• Catastrophic wrong-route administration

Some complications may be permanent, including:

• Peripheral neuropathy
• Hearing loss
• Cardiac dysfunction
• Pulmonary fibrosis
• CNS injury
• Renal impairment

Important Modernization of the Older Source

• Antineoplastic poisoning is highly agent- and route-specific.
• Early asymptomatic appearance does not exclude serious delayed toxicity.
• Serial CBC monitoring is crucial because myelosuppression may be delayed.
• Methotrexate toxicity requires protocol-guided leucovorin rescue, hydration, urinary alkalinization, and serial concentrations.
• Glucarpidase is an important modern treatment for selected high-dose methotrexate toxicity with renal dysfunction and delayed elimination.
• Repeated accidental daily methotrexate dosing is an important modern poisoning pattern.
• Uridine triacetate is the specific emergency antidotal therapy for selected 5-FU/capecitabine overdoses and early severe fluoropyrimidine toxicity.
• DPD deficiency can produce catastrophic fluoropyrimidine toxicity at otherwise therapeutic exposure.
• Mesna prevents urothelial injury from ifosfamide and selected cyclophosphamide regimens.
• Ifosfamide can cause severe encephalopathy.
• Dexrazoxane has roles in anthracycline cardioprotection and anthracycline extravasation.
• Intrathecal vincristine is a catastrophic, potentially fatal wrong-route error.
• Extravasation treatment is drug specific; saline injection to dilute a vesicant is not a universal modern recommendation.
• Bleomycin exposure does not mean withholding oxygen from a hypoxemic patient.
• Fever with significant chemotherapy-induced neutropenia requires urgent empiric infection management.
• G-CSF decisions should be individualized rather than based on one historic cell-count threshold.
• The historical bicarbonate/lidocaine/bretylium sequence is not a universal treatment for chemotherapy-related dysrhythmia; bretylium is obsolete.
• Ipecac and routine gastric lavage are obsolete.
• Trendelenburg and dopamine-first shock management are outdated.
• Fixed 6-hour observation is inadequate for drugs with delayed marrow or organ toxicity.
• Historical FDA pregnancy categories are obsolete.

Key Points

• Antineoplastic toxicity is drug-, dose-, route-, and time-dependent.
• Delayed myelosuppression is one of the most important dangers.
• Methotrexate → leucovorin rescue; glucarpidase for selected severe delayed elimination with renal dysfunction.
• 5-FU/capecitabine → uridine triacetate for qualifying overdose or early severe toxicity.
• Cisplatin → nephrotoxicity, electrolyte wasting, ototoxicity, neuropathy.
• Cyclophosphamide/ifosfamide → hemorrhagic cystitis; mesna is protective.
• Ifosfamide → encephalopathy.
• Anthracyclines → cardiotoxicity and severe extravasation injury.
• Vincristine → neurotoxicity; intrathecal administration is catastrophic.
• Bleomycin → pulmonary toxicity.
• Asparaginase → pancreatitis, coagulopathy/thrombosis, hyperglycemia, hypersensitivity.
• A normal early CBC does not rule out later severe toxicity.
• Significant exposures require early toxicology, oncology, pharmacy, and poison-center coordination with prolonged follow-up when indicated.